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Background: Accurate and sensitive detection of BRCA1/2 germ-line mutations is crucial for the clinical manage-
ment ofwomen affected by breast cancer, for prevention and, notably, also for the identiﬁcation of at-risk healthy rel-
atives. The most widely used methods for BRCA1/2molecular analysis are Sanger sequencing, and denaturing high
performance liquid chromatography (dHPLC) followed by the Sanger method. However, recent ﬁndings suggest
that next-generation sequencing (NGS)-based approaches may be an efﬁcient tool for diagnostic purposes. In this
context, we evaluated the effectiveness of NGS for BRCA gene analysis compared with dHPLC/Sanger sequencing.
Methods: Seventywomenwere screened for BRCA1/2mutations by both dHPLC/Sanger sequencing andNGS, and the
data were analyzed using a bioinformatic pipeline.
Results: Sequence data analysis showed thatNGS ismore sensitive in detectingBRCA1/2 variants than the convention-
al procedure, namely, dHPLC/Sanger.
Conclusion:Next-generation sequencing ismore sensitive, faster, easier touseand less expensive than the convention-
al Sanger method. Consequently, it is a reliable procedure for the routine molecular screening of the BRCA1/2 genes.© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
BRCA1 and BRCA2 are the most important genes predisposing to
inherited breast and ovarian cancers [1]. Germline mutations in these
two highly penetrant genes can increase the lifetime risk of developing
these tumors by as much as 80%, and are also associated with an earlier
onset of disease.Moreover, other kinds of cancers (i.e. prostate, pancreatic
and gastric cancers) are more common in BRCA1 and BRCA2 carriers than
in the general population [2]. Therefore, early identiﬁcation of carriers
amongwomen affected by breast or ovarian cancer is crucial to enable pa-
tient stratiﬁcation and to guide clinicians in deciding themost appropriate
therapeutic strategy and follow-up program. In addition, accurate genetic
counseling can identify at-risk healthymembers of affected families, who
can then be enrolled in appropriate surveillance programs.gh-performance liquid chroma-
eneration sequencing; TN, true
zate, Dipartimento di Medicina
ansini 5, 80131 Naples, Italy.
. This is an open access article underDirect Sanger sequencing continues to be the routine procedure for
the molecular analysis of the BRCA genes [3,4]. However, given the large
size of both BRCA1 and BRCA2 and the consequent cost of their direct se-
quencing, large-scale mutation scanning strategies such as denaturing
high-performance liquid chromatography (dHPLC) and high-resolution
melting, are also commonly used pre-sequencing methods [5,6]. By dra-
matically increasing the throughput of sequencing and reducing its
costs, next-generation sequencing (NGS) has had a major impact on sev-
eral ﬁelds of molecular research [7–9]. Furthermore, NGS is increasingly
being applied in the ﬁeld of diagnostics, including BRCA analysis [10–15].
Here, we report the outcome of an evaluation study conducted to as-
sess the analytic performances of an NGS-based strategy for the molec-
ular analysis of the BRCA1 and BRCA2 genes versus a well established,
commonly used, dHPLC/Sanger sequencing strategy.2. Materials and methods
2.1. Enrollment of patients and sample collection
Seventy women attending the Breast Unit, Istituto Nazionale dei
Tumori, Fondazione G. Pascale in Naples, were consecutively enrolledthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Fig. 1. Complete workﬂow of the two analytic strategies, dHPLC/Sanger and NGS, used to analyze the 70 at risk women.
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which they were informed about the signiﬁcance of molecular screening,
provided information about their personal and familial history, and gave
written informed consent to the study. The 70 enrolled women had at
least one of the following conditions: early-onset breast cancer (BC)
(diagnosed at 35 years or earlier); bilateral BC;multiple organ cancers, in-
cluding BC; BC diagnosed at any agewith at least oneﬁrst- or two second-
degree relativeswith breast and/or ovarian cancer; BCdiagnosedwith ad-
vanced tumor staging; and patients with benign mammary alterationsTable 1
BRCA1 variants identiﬁed in the analyzed population by dHPLC/Sanger and NGS.
Exon/intron HGVS1 cDNA HGVS1 protein Mutation type Clin
IVS7 c.442-3_442− 3delT – Deletion Un
9 c.591C N T p.Cys197Cys Synonymous Pol
IVS10 c.671-12_671 + 12delG – Deletion Un
11 c.1067A N G p.Gln356Arg Missense Un
11 c.1911 T N C p.Thr637Thr Synonymous Un
11 c.2077G N A p.Asp693Asn Missense Pol
11 c.2082C N T p.Ser694Ser Synonymous Un
11 c.2311 T N C p.Leu771Leu Synonymous Un
11 c.2612C N A p.Pro871Gln Missense Pol
11 c.3113A N G p.Glu1038Gly Missense Pol
11 c.3119G N A p.Ser1040Asn Missense Un
11 c.3418A N G p.Ser1140Gly Missense Un
11 c.3419G N T p.Ser1164Ile Missense Del
11 c.3548A N G p.Lys1183Arg Missense Pol
11 c.3711A N G p.Ile1237Met Missense Un
13 c.4308 T N C p.Ser1436Ser Synonymous Pol
14 c.4484G N T p.Arg1495Met Missense Del
16 c.4837A N T p.Ser1613Cys Missense Un
16 c.4837A N G p.Ser1613Gly Missense Pol
16 c.4843G N A p.Ala1615Thr Missense Un
16 c.4956G N A p.Met1652Ile Missense Un
16 c.4964_4982del p.Ser1655_Glu1661fs Frameshift Del
IVS18 c.5153-1G N C – Substitution Del
1 All identiﬁed variants are indicated both by cDNA base sequence (second column) and by p
nomenclature guidelines.
2 Breast Cancer Information Core (http://research.nhgri.nih.gov/bic/).
3 n.r., not reported in NCBI (National Center for Biotechnology Information) database.with a BC-positive family history. The latter group consisted of 18 patients
and can be considered a small control cohort.
A blood EDTA samplewas collected fromeach subject. GenomicDNA
was isolated from peripheral blood using the Nucleon BACC3 Genomic
DNAExtraction Kit (GEHealthcare, Life Sciences, Little Chalfont, UK), ac-
cording to the manufacturer's instructions. The quality of DNA samples
was assessed by agarose gel electrophoresis and their quantity was
evaluated with the NanoDrop 2000c Spectrophotometer (Thermo Fish-
er Scientiﬁc, Waltham, MA, USA).ical relevance (BIC)2 Reference ID according
to NCBI
Number of times a variant was
observed (dHPLC + Sanger/NGS)
known n.r.3 1/1
ymorphism rs1799965 1/1
known n.r.3 1/1
known rs1799950 15/20
known n.r.3 1/1
ymorphism rs4986850 14/17
known rs1799949 31/39
known rs16940 30/38
ymorphism rs799917 23/42
ymorphism rs16941 36/36
known rs4986852 3/3
known rs2227945 0/1
eterious n.r.3 1/1
ymorphism rs16942 33/37
known rs80357388 0/1
ymorphism rs1060915 11/37
eterious rs80357389 0/1
known rs1799966 1/1
ymorphism rs1799966 32/38
known rs80356987 1/1
known rs1799967 0/1
eterious rs80359876 1/1
eterious rs80358137 1/1
rotein sequence (third column) according to theHGVS (HumanGenomeVariation Society)
Table 2
BRCA2 variants identiﬁed in the analyzed population by dHPLC/Sanger and NGS.
Exon/intron HGVS1 cDNA HGVS1 Protein Mutation type Clinical relevance
(BIC)2
Reference ID according
to NCBI
Number of times a variant was
observed (dHPLC + Sanger/NGS)
10 c.865A N C p.Asn289His Missense Polymorphism rs766173 6/6
10 c.865A N G p.Asn289Asp Missense Unknown rs766173 1/1
10 c.1114C N A p.His372Asn Missense Polymorphism rs144848 26/56
10 c.1124C N T p.Pro375Leu Missense Unknown rs80358409 0/1
10 c.1151C N T p.Ser384Phe Missense Polymorphism rs41293475 0/1
10 c.1365A N G p.Ser455Ser Synonymous Polymorphism rs1801439 8/8
IVS10 c.1909 + 12_1909 + 12delT – Deletion Unknown n.r.3 1/1
11 c.2229 T N C p.His743His Synonymous Polymorphism rs1801499 5/5
11 c.2971A N G p.Asn991Asp Missense Polymorphism rs1799944 4/6
11 c.3396A N G p.Lys1132Lys Synonymous Polymorphism rs1801406 28/29
11 c.3807 T N C p.Val1269Val Synonymous Polymorphism rs543304 19/31
11 c.3824 T N C p.Ile1275Thr Missense Unknown rs80358625 0/1
11 c.4131_4132insTGAGA p.Asn1377_Thr1378 In Frame Insertion Deleterious rs80359429 1/2
11 c.4563G N A p.Lys1521Lys Synonymous Polymorphism rs206075 27/69
11 c.4585G N A p.Gly1529Arg Missense Polymorphism rs28897728 1/1
11 c.5199C N T p.Ser1733Ser Synonymous Polymorphism rs28897734 1/2
11 c.5312G N A p.Gly1771Asp Missense Polymorphism rs80358755 1/3
11 c.3515C N G p.Ser1172Trp Missense Unknown rs80358600 0/2
11 c.5744C N T p.Thr1915Met Missense Polymorphism rs4987117 3/1
11 c. 6037A N T p.Lys2013Ter Nonsense Deleterious rs80358840 1/1
22 c.6486_6489delACAA p.Lys2162_Gln2163fs Frameshift Deleterious rs80359598 1/1
11 c.6513C N G p.Val2171Val Synonymous Polymorphism rs206076 45/69
14 c.7242A N G p.Ser2414Ser Synonymous Polymorphism rs1799955 16/23
14 c.7354A N G p.Asn2452Asp Missense Unknown rs398122580 1/1
IVS16 c.7806-14 T N C – Deletion Unknown rs9534262 1/1
27 c.9976A N T p.Lys3326Ter Nonsense Polymorphism rs11571833 1/1
1 All identiﬁed variants are indicated both by cDNA base sequence (second column) and by protein sequence (third column) according to theHGVS (HumanGenomeVariation Society)
nomenclature guidelines.
2 Breast Cancer Information Core (http://research.nhgri.nih.gov/bic/).
3 n.r., not reported in NCBI (National Center for Biotechnology Information) database.
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The combined dHPLC/SURVEYOR® Nuclease approach
(Transgenomic, Omaha, NE, USA) was used for molecular BRCA1
and BRCA2 screening, as previously described [5]. Brieﬂy, PCR am-
pliﬁcations were performed using speciﬁc primer pairs to amplify
all the BRCA1 and BRCA2 coding exons and their ﬂanking regions
using a multiamplicon approach (Supplemental Table 1). After am-
pliﬁcation, each PCR reaction/sample was digested by SURVEYOR®
Nuclease using 15 μL of a 1:1 mixture of DNA amplicons of each
sample and wild-type DNA, 1.5 μL of 0.15 mM MgCl2, 1.5 μL of En-
hancer Cofactor and 1.0 μL of SURVEYOR Nuclease (Transgenomic).
The reactions were incubated at 42 °C for 60 min and stopped by
adding 1.5 μL of stop buffer. For each amplicon pool, a gradient
was chosen using Navigator software (Transgenomic) based on
the size of the PCR fragments. Fragments were analyzed by HPLC
on the TransgenomicWAVE Nucleic Acid High Sensitivity Fragment
Analysis System (WAVE HS system; Transgenomic). Amplicon re-
actions that showed a dHPLC proﬁle suggestive of mutations were
selected for Sanger sequencing conﬁrmation. Direct sequencing
was performed with an ABI 3100 capillary sequencer (AppliedTable 3
Analytic performances of DHPLC/Sanger and NGS methods in detecting BRCA 1/2 sequence var
DHPLC/Sanger
BRCA1 BRCA2
N total variants 237 198
N unique variants 19 (7 SNPs,
9 UCV,
3 causative mutations)
22 (15 SNP
3 UCV,
4 causative
Analytic sensitivity % (95% CI) 67.6 (63.9–71.1)
Analytic speciﬁcity % (95% CI) 100 (100)
PPV % 100
NPV % 99.98
N, number; SNP, single nucleotide polymorphism; UCV, unknown signiﬁcance variant; CI, conﬁBiosystems Inc., Foster City, CA, USA). Sanger electropherogram
evaluation was carried out using the SeqMan tool (DNASTAR, Inc.,
Madison, Wisconsin, USA).
2.3. NGS sequencing
Multiple amplicon DNA libraries, covering all the BRCA1 and BRCA2
coding exons and their ﬂanking regions, were obtained using the
BRCA MASTR v2.1 Assay kit (Multiplicom, Niel, Belgium), following
the manufacturer's instructions. In brief, for each patient, 250 ng of ge-
nomic DNA was used to perform 5 multiplex PCR reactions able to am-
plify the entire target region. Then, a 1:1000 dilution of each multiplex
PCRwas re-ampliﬁed using hybrid primers to univocally tag all themul-
tiplexes from the same patient with a barcode sequence (MID). These
primers contained a universal adaptor sequence that is required for
downstream sequencing reactions. The multiplexed tagged reactions
were puriﬁed using Agencourt AMPure XP Beads (Beckman Coulter,
Brea, CA, USA), quantiﬁed using the NanoDrop 2000c Spectrophotome-
ter (Thermo Fisher Scientiﬁc, Waltham,MA, USA), and quality-assessed
using the Experion DNA 1 kb Analysis kit (Bio-Rad, Hercules, CA, USA).
Equimolar amounts of the 5 multiplexed tagged reactions from theiants.
NGS
BRCA1 BRCA2
320 323
s,
mutations)
23 (7 SNPs,
12 UCV,
4 causative mutations)
26 (16 SNPs,
6 UCV,
4 causative mutations)
100 (99.4–100)
100 (100)
100
100
dence interval; PPV, positive predictive value; NPV, negative predictive value.
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libraries were pooled and sequenced using the Genome Sequencer FLX
System (454-Life Science and Roche, Branford, CO, USA), according to
the manufacturer's instructions. Causative mutations or doubtful vari-
ants were conﬁrmed by Sanger sequencing.
2.4. NGS data analysis
NGS sequence data were analyzed using the SeqPilot software (ver-
sion 3.5.2) from JSI Medical Systems (www.jsi-medisys.de). The BRCA1
(ENSG00000012048 for gene reference and ENST00000357654 for
transcript) and BRCA2 (ENSG00000139618 and ENST00000380152 re-
spectively) sequences from the NCBI-database (http://www.ncbi.nlm.
nih.gov) were used as reference sequences. Raw sequencing data were
directly uploaded in the software and, for each MID, blasted against a
target reference sequence. Thus, we obtained a report/patient contain-
ing the sequence-coverage/exon and the list of high conﬁdence variants.
According to the manufacturer's protocol, a minimum absolute cover-
age/exon of 40× is allowed and only variants present in both directions
and with a minimum coverage of 10% default, excluding homopoly-
mers, were contemplated in the genetic analysis. All sequence variants
are named according to the nomenclature used by the Human Genome
Variation Society, HGVS (http://www.hgvs.org). The signiﬁcance of var-
iants was attributed according to the Breast Cancer Mutation database,
BIC (http://research.nhgri.nih.gov/projects/bic/), and the Ensemble Da-
tabase (http://www.ensembl.org).
2.5. Assessment of methodology performance
The sensitivity and speciﬁcity of the described procedures were
assessed by evaluating their ability to correctly identify all the base
changes identiﬁed in the same population by direct Sanger sequencing
of all BRCA1 and BRCA2 exons. As speciﬁed above, missing Sanger data
were obtained after the NGS analysis to determine if a speciﬁc variant
was present or not, andwere used as gold standard to identify each sub-
stitution as true positive (TP), true negative (TN), false positive (FP) or
false negative (FN), and to assess the analytic performances of the two
approaches used. Sensitivity and speciﬁcity were calculated using the
following formulas: sensitivity = TP / (TP + FN); speciﬁcity = TN /
(TN+ FP). Conﬁdence intervals for sensitivity and speciﬁcity were esti-
mated with the Pearson–Klopper method, and the R statistical software
environment.
3. Results
The BRCA1 and BRCA2 genes were analyzed in the 70 enrolled sub-
jects using the two analytic strategies described under Section 2
(Fig. 1). The combined dHPLC/Surveyor® nuclease strategy revealed
237 and 198 variants in BRCA1 and BRCA2, respectively, and these
were conﬁrmed by Sanger sequencing. These variants correspond to
19 BRCA1 variants, i.e., 7 polymorphisms, 9 variants of unknown signif-
icance (UCVs) and 3 causativemutations (Table 1), and to 22 BRCA2 var-
iants, i.e., 15 polymorphisms, 3 UCVs, and 4 causative mutations
(Table 2). The NGS-based strategy revealed 320 and 323 variants in
BRCA1 and BRCA2, respectively. These variants correspond to 23 BRCA1
variants, namely, 7 polymorphisms, 12 UCVs, and 4 causativemutations
(Table 1), and 26 BRCA2 variants, namely, 16 polymorphisms, 6 UCVs,
and 4 causative mutations (Table 2).
Comparative analysis of the results obtained with the two analytic
strategies showed that all the variants detected by the routinely used
dHPLC/Sanger method were identiﬁed also by NGS. Interestingly, the
NGS technique identiﬁed variants missed by conventional screening
(Tables 1 and 2). Additional Sanger sequencingwas carried out to assess
all these discrepancies and conﬁrmed the NGS data.
We assessed the reliability of theNGS-based approach by comparing
the NGS results to the Sanger sequencing results (Table 3). While thespeciﬁcity was 100% for both methods, the NGS-based procedure had
a higher sensitivity (100% versus 67.6%), which is in linewith a previous
report [16]. In addition, in our study the NGS-based method had also a
higher diagnostic sensitivity since it was able to detect a causative
BRCA1 mutation missed by traditional screening (Table 3).
In terms of analytical time, it took about three months to analyze all
the 70 enrolled subjects using the dHPLC/Sanger approach, and only
10 days using NGS. In addition, the cost of NGS reagents was half that
of the reagents required for the dHPLC/Sanger procedure.
4. Discussion
Thanks to the recent development of NGS technologies, and the con-
sequent decreased cost of DNA sequencing, a wide range of technical
possibilities are now available for studies aimed at elucidating the mo-
lecular basis of human diseases [17]. In addition, these technologies
are now beginning to be exploited for diagnostic purposes. Therefore,
it is conceivable that in the near future NGS may become an invaluable
tool for both clinical biochemists and clinicians. In fact, increasing evi-
dence indicates that information about the BRCA1 and BRCA2mutation
status, especially if available in a timely fashion, will enable a patient
and her/his health-care provider tomake informed decisions about can-
cer prevention, screening and treatment [18].
In this optics, we evaluated the efﬁcacy of an NGS-based method for
the molecular analysis of BRCA1 and BRCA2 in 70 patients using both
dHPLC/Sanger and NGS-based strategies. Here, we demonstrate that
NGS ismore sensitive than the conventional approaches in detecting se-
quence variants. In addition, since we analyzed up to 70 samples in the
same sequencing run, also the time and cost of the analysis were greatly
reduced. Given these results, this NGS-based approach to the detection
of BRCA1/BRCA2 mutations is suitable for use in a routine diagnostic
workﬂow.
Although several NGS-based procedures have been proposed for the
molecular diagnosis of the predisposition for breast cancer, our study
demonstrates that NGS-based tests are more sensitive, faster, easier to
use, and less expensive than the conventional Sanger method, which
is the most widely test currently used and is considered the gold stan-
dard test.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.cca.2015.03.045.
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